Lifetime Citizen Portal Access — AI Briefings, Alerts & Unlimited Follows
Senate committee hears wide-ranging pharmacy bill to expand pharmacists’ roles and modernize rules
Loading...
Summary
Sponsors and pharmacists told the Senate Health and Human Services Committee that SB504 would allow oncology clinics to dispense 30-day supplies of certain oral anticancer drugs, permit remote processing for advanced pharmacy technicians, modernize license display rules and clarify collaborative practice language; the New Hampshire Medical Society urged tighter limits and preserved training requirements.
Sen. David Roche, the prime sponsor, told the committee SB504 is largely technical cleanup while expanding opportunities for pharmacists to speed patient access to care. "It will allow the dispensing of a 30 day supply of a non controlled oral cancer anticancer medication by [a] licensed health care professional legally authorized to prescribe that," he said, arguing the change would reduce delays in starting chemotherapy.
The bill would also update licensing rules to reflect modern practice — changing a requirement that a pharmacist’s license be "conspicuously displayed" at each location to making it "readily retrievable" — and permit licensed advanced pharmacy technicians to perform remote processing tasks such as data entry and drug utilization review.
Why it matters: Proponents, including pharmacists and the Department of Health and Human Services (DHHS), said the measures would improve timely access to treatment and support rural care. Patricia Tilley, Associate Commissioner at DHHS, said the department supports SB504 and noted the changes align with CMS rural health transformation goals. David Chorney of the governor’s Go North office warned that implementing certain scope commitments is tied to competitive federal grant scoring and future funding.
Supporters from pharmacy organizations described how pharmacists already deliver clinical services under collaborative practice agreements. "Pharmacists are educated on evidence based clinical decision making, therapeutic treatment planning, which includes diagnosis and prescribing," Amanda Morrill, president of the New Hampshire Pharmacists Association, told the panel, adding pharmacists complete a four‑year PharmD plus clinical hours and continuing education.
Concerns and limits: The New Hampshire Medical Society urged clearer boundaries. Kathy Stratton, the society’s CEO, testified she worries SB504 blurs the line between medical diagnosis and the practice of pharmacy, particularly on "prescribing, ordering, administering, and interpretation of laboratory tests," and asked for clearer CPA language and continued credentialing or training requirements.
Procedural next steps: Chairman directed stakeholders — pharmacy organizations and the medical society — to reconcile language and return within a week. The hearing closed with the committee reserving the right to amend the bill after stakeholder discussions.
Context: Sponsor testimony emphasized both technical corrections (license display, electronic tracking of pharmacist involvement) and policy shifts toward a standards-of-care model for pharmacy practice similar to other health professions. The committee indicated willingness to add clarifying language (for example, making collaborative practice participation "voluntary").
The committee did not take a final vote on SB504 at this session; members asked parties to negotiate outstanding items and return with proposed amendments.
